MG56 grass pollen immunotherapy

MG56 is an investigational allergen immunotherapy (AIT) product developed by INMUNOTEK for the treatment of allergic rhinitis and allergic rhinoconjunctivitis caused by grass pollen. The formulation consists of a 50/50 mixture of polymerized allergoids from *Phleum pratense* (Timothy grass) and *Dactylis glomerata* (Orchard grass), which are chemically conjugated to non-oxidized mannan from *Saccharomyces cerevisiae* using glutaraldehyde. This mannan-conjugation technology is designed to target the allergoids to dendritic cells via C-type lectin receptors (such as the mannose receptor), promoting the induction of allergen-specific T-cell tolerance and shifting the immune response away from the Th2-mediated IgE production characteristic of allergies. MG56 has been evaluated in Phase 2 clinical trials for both subcutaneous (SCIT) and sublingual (SLIT) administration.

Other names

mannan-conjugated polymerized allergoids of Phleum pratense and Dactylis glomerata